Abstract
Treatment options for metastatic renal cell carcinoma (mRCC) have recently increased with the development of various agents that inhibit vascular endothelial growth factor (VEGF) elements and rapamycin pathways. Sunitinib, a multi-target VEGF receptor tyrosine kinase inhibitor(TKI) and c-kit, showed disease-free survival gain compared to interferon alfa in a phase III study. Although Suni…